Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Philip J. Mease, MD

Rheumatologist, Director of Rheumatology Research, Clinical Professor Director of Rheumatology Research Swedish Medical Center/Providence-St Joseph Health
Swedish Medical Center/Providence St. Joseph Health
Seattle, Washington, United States

Dr. Mease received undergraduate and medical degrees from Stanford University, completed residency in internal medicine and fellowship in rheumatology at the University of Washington, directs the rheumatology research division at Swedish Medical Center/Providence St. Joseph Health and is Clinical Professor of Medicine at the University of Washington in Seattle. Research interests include psoriatic arthritis (PsA) and spondyloarthritis (SpA), including disease state, development of outcome measures, and determining the efficacy and safety of emerging therapies. He has authored over 700 journal articles, 1000 abstracts, and many book chapters. Expertscape designation: most published person in world on PsA and psoriasis. Founding organizer and current treasurer of the Group for Research and Assessment of Psoriasis and PsA (GRAPPA). Member of the Assessment of Spondyloarthritis international Society (ASAS) and the Spondyloarthritis Research and Treatment Network (SPARTAN). Active in the Outcome Measures in Rheumatology Clinical Trials (OMERACT) organization. Scientific director of PsA and SpA arms of the Consortium of Rheumatology Researchers of North America (Corrona/CorEvitas) registry. Awards: National Psoriasis Foundation 2019 lifetime achievement award for his work in advancing the field of PsA; Arthritis Foundation Legacy award; Rheumatology Winter Clinical Symposium Kahuna award for excellence in education.

Presentation(s):

  • IT26S6: Dual Perspectives in Psoriatic Disease Management: Zero Disease Activity in One or More Domains

    Sunday, October 26, 2025
    10:30 AM - 11:15 AM Central Time

    Disclosure information not submitted.

  • 0579: Characteristics and Treatment Patterns among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Disease-Modifying Antirheumatic Drug Therapy

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 0581: Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 0580: Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 0578: Real-world Effectiveness of Upadacitinib on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Core Domains for Patients with Psoriatic Arthritis: Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • IT26S5: A Product Theater for Zepbound® (tirzepatide) Injection Including an Affordability Solution for Taltz® (ixekizumab) Patients

    Sunday, October 26, 2025
    3:30 PM - 4:15 PM Central Time

    Disclosure information not submitted.

  • ITS12: Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition

    Sunday, October 26, 2025
    5:30 PM - 7:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 1178: An International Modified Delphi Study on the Evolving Role of Janus Kinase Inhibitors (JAKi) in Rheumatic and Musculoskeletal Diseases (RMDs)

    Monday, October 27, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 1458: Clinical Efficacy of Bimekizumab Treatment up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies

    Monday, October 27, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 1454: Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies

    Monday, October 27, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 1456: Long-Term Safety of Tildrakizumab Through Week 208 in Patients With Psoriatic Arthritis: Results From the Phase 2b Open-Label Extension Study

    Monday, October 27, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 1453: Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors

    Monday, October 27, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 1457: Real-world Patient Trajectories in Psoriasis and Psoriatic Arthritis: a Retrospective Study

    Monday, October 27, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 1455: Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design

    Monday, October 27, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 2366: Association Between Skin and Joint Symptom Control and Patient-reported Pain and Health Status Among Patients with Psoriatic Arthritis in the Corevitas Psoriatic Arthritis/spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drugs

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 2368: Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 2367: Real-World Effectiveness of Risankizumab on Axial Symptoms in Biologic-Naïve Patients With Psoriatic Arthritis in the United States and Europe

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 2369: Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Interleukin-17A Inhibitors

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 2365: Sustained Efficacy up to 3 Years with Bimekizumab Treatment Across GRAPPA Core Domains in Patients with Psoriatic Arthritis: Long-Term Results from Two Phase 3 Trials

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)